Literature DB >> 16963547

Chronic obstructive pulmonary disease, risk factors, and outcome trials: comparisons with cardiovascular disease.

Scott D Ramsey1, F D Richard Hobbs.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a major health problem and now ranks fifth in terms of the global burden of disease. Although COPD is a disease that is characterized by progressive respiratory symptoms and functional decline, exacerbations pose the greatest risk for morbidity and early mortality, have a dramatic effect on quality of life, and are the most significant source of health care expenditure. To improve survival and reduce costs, it is critical to develop effective programs designed to reduce the frequency and severity of exacerbations for these patients. With limited health care resources, efficient and effective management of COPD ideally involves identifying and focusing efforts on individuals at particular risk. In the development of an appropriate multimodal strategy, lessons could be learned from the evolution of guidelines and management of cardiovascular disease, in particular heart failure, which has many parallels with COPD in terms of prevalence, prognosis, and impact on patient quality of life. There is a need for large prospective trials in COPD, based on hard clinical outcomes such as death, which, together with physician and patient education, will help to drive improvements in clinical management.

Entities:  

Mesh:

Year:  2006        PMID: 16963547     DOI: 10.1513/pats.200603-094SS

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  18 in total

1.  COPD and death: what exactly is the relationship?

Authors:  Michael Rudolf
Journal:  Thorax       Date:  2007-05       Impact factor: 9.139

2.  Effectiveness of Umeclidinium-Vilanterol for Protocolized Management of Chronic Obstructive Pulmonary Disease Exacerbation in Hospitalized Patients: A Sequential Period Analysis.

Authors:  Todd W Chapin; Michael A Mann; Gary L Brown; Traci L Leitheiser; Becky Anderson; David D Leedahl
Journal:  Chronic Obstr Pulm Dis       Date:  2018-01-24

3.  Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD.

Authors:  Jane F Chisholm; Siddharth K Shenoy; Julie K Shade; Victor Kim; Nirupama Putcha; Kathryn A Carson; Robert Wise; Nadia N Hansel; Justin S Hanes; Jung Soo Suk; Enid Neptune
Journal:  Eur Respir J       Date:  2019-08-01       Impact factor: 16.671

4.  Overview of the Impact of Depression and Anxiety in Chronic Obstructive Pulmonary Disease.

Authors:  Josep Montserrat-Capdevila; Pere Godoy; Josep Ramon Marsal; Ferran Barbé; Josep Pifarré; Miquel Alsedà; Marta Ortega
Journal:  Lung       Date:  2016-11-29       Impact factor: 2.584

5.  Heart Rate Variability on 10-Second Electrocardiogram and Risk of Acute Exacerbation of COPD: A Secondary Analysis of the BLOCK COPD Trial.

Authors:  David M MacDonald; Takudzwa Mkorombindo; Sharon X Ling; Selcuk Adabag; Richard Casaburi; John E Connett; Erika S Helgeson; Janos Porszasz; Harry B Rossiter; William W Stringer; Helen Voelker; Dongxing Zhao; Mark T Dransfield; Ken M Kunisaki
Journal:  Chronic Obstr Pulm Dis       Date:  2022-04-29

Review 6.  Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness.

Authors:  Farzaneh Sanei; Tom Wilkinson
Journal:  Ther Adv Respir Dis       Date:  2016-05-18       Impact factor: 4.031

7.  A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology.

Authors:  Robert Wilson; Antonio Anzueto; Marc Miravitlles; Pierre Arvis; Geneviève Faragó; Daniel Haverstock; Mila Trajanovic; Sanjay Sethi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-06-29

8.  The impact of body mass index on inpatient- versus outpatient-treated chronic obstructive pulmonary disease exacerbations.

Authors:  Ariane Jacob; Catherine Laurin; Kim L Lavoie; Gregory Moullec; Maxine Boudreau; Catherine Lemière; Simon Bacon
Journal:  Can Respir J       Date:  2013-05-28       Impact factor: 2.409

Review 9.  Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena.

Authors:  David Halpin
Journal:  COPD       Date:  2008-06       Impact factor: 2.409

Review 10.  Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.

Authors:  Marc Miravitlles; Anthony D'Urzo; Dave Singh; Vladimir Koblizek
Journal:  Respir Res       Date:  2016-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.